Compare Incyte Corporation (INCY) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.27 (market cap $28.69M). The key difference: Incyte Corporation is far larger — about 796.4× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 61 Days on average.
| INCY | QDTY | |
|---|---|---|
Market Cap | $22.85B | $28.69M |
Volume | 1,927,029 | 22,490 |
Sector | Health | Income / Options Overlay |
52-Week High | $129.93 | $46.71 |
52-Week Low | $83.80 | $36.57 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
QDTY trades at $39.27, down 0.84% today, with a bullish technical signal supported by moving averages. The ETF demonstrates strong dividend distribution activity with recent payouts ranging from $0.19 to $0.30 per share, highlighted by a $0.24 dividend announced October 6th, 2026 representing a significant yield. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while overall trend remains positive.
The outlook remains favorable for income-focused investors given the consistent dividend payments, though elevated RSI levels suggest near-term caution. Key risks include market volatility affecting covered call strategies and interest rate sensitivity. The ETF's weekly distribution model provides regular income but requires monitoring of underlying Nasdaq 100 performance for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
